TY - JOUR
T1 - Consensus Statements on Precision Oncology in the China Greater Bay Area
AU - Lam, Tai-Chung
AU - Cho, William Chi-Shing
AU - Au, Joseph Siu-Kie
AU - Ma, Edmond Shiu-Kwan
AU - Lam, Stephen Tak-Sum
AU - Loong, Herbert Ho-Fung
AU - Wong, Jason Wing Hon
AU - Wong, S.N. Michael
AU - Lee, Victor Ho-Fun
AU - Leung, Roland Ching-Yu
AU - Lau, Johnny Kin-Sang
AU - Kam, Michael Tsz-Yeung
AU - Mok, Florence Siu-Ting
AU - Lim, Fiona Mei-Ying
AU - Nyaw, Jonathan Shi-Feng
AU - Tin, Winnie Wing-Yan
AU - Cheung, Ka-Man
AU - Chan, Oscar Siu-Hong
AU - Kwong, Philip Wai-Kay
AU - Cheung, Foon-Yiu
AU - Poon, Darren M.C.
AU - Chik, Jeannie Yin-Kwan
AU - Lam, Martin Ho-Ching
AU - Chan, Lawrence Wing-Chi
AU - Wong, Sze-Chuen Cesar
AU - Cao, Ya-Bing
AU - Hui, Cheng-Vai
AU - Chen, Jack Zhi-Jian
AU - Chang, Jian-Hua
AU - Kong, Spring Feng-Ming
AU - El Helali, Aya
N1 - doi: 10.1200/PO.22.00649
PY - 2023/6
Y1 - 2023/6
N2 - BACKGROUNDNext-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA.METHODSThirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0.RESULTSThe POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice.CONCLUSIONPOWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.
AB - BACKGROUNDNext-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA.METHODSThirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0.RESULTSThe POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice.CONCLUSIONPOWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.
U2 - 10.1200/PO.22.00649
DO - 10.1200/PO.22.00649
M3 - Journal article
SN - 2473-4284
SP - e2200649
JO - JCO Precision Oncology
JF - JCO Precision Oncology
IS - 7
ER -